Frank Pallone actually said...
I mean because we have all heard that--well, I guess the GPhA commissioned a study looking into the economic impact of the FDA rule, and it concluded that finalizing the FDA rule will lead to new liability protection costs for the generic drug industry of about $4 billion a year, and yet the cost attributable to the FDA rule sound like they may be, you know, really not different from the liability cost the industry faced prior to Mensing.
Context
Pallone questions the economic impact of the FDA rule on generic drug liability costs.
03/31/2014